Lung Cancer Clinical Trials: Current Options and How to Enroll
Written by North Editorial Staff | Clinically reviewed by Laura Morrissey, RN, BSN | Last reviewed: February 2026
Key Takeaways
The lung cancer clinical trial landscape is expansive and diverse: More than 1,500 active lung cancer clinical trials in the U.S. offer access to innovative treatments across all disease stages and histologies.
NSCLC trials dominate the landscape with robust options in targeted therapy (EGFR, ALK, ROS1, KRAS G12C), immunotherapy combinations, and novel drug classes like ADCs and bispecific antibodies.
SCLC trials are expanding hope: While historically limited, SCLC clinical trials now offer immunotherapy combinations, DLL3-targeting therapies, and BiTE approaches showing genuine promise.
Your oncologist is essential: Start every trial exploration by discussing options with your oncologist, who can assess your eligibility and facilitate referrals to appropriate trials.
Trial matching services simplify the search: Tools like North's trial finder can help you quickly identify trials aligned with your specific diagnosis, biomarker status, and preferences.
Informed participation protects you: Understanding trial design, costs, risks, and your rights ensures you make decisions aligned with your values and goals.
Introduction
Lung cancer has one of the most active and rapidly evolving clinical trial landscapes in oncology today. According to the National Cancer Institute, more than 1,500 lung cancer clinical trials are currently recruiting patients in the United States alone—offering unprecedented access to innovative treatments, combination therapies, and personalized approaches that may not yet be available through standard care. Whether you've been diagnosed with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or are at risk for lung cancer, clinical trials represent a genuine opportunity to access cutting-edge treatments while contributing to the research that advances care for future patients.
The lung cancer clinical trial landscape has transformed dramatically over the past five years. Advances in immunotherapy, breakthrough treatments targeting specific genetic biomarkers, and novel drug classes like antibody-drug conjugates (ADCs) and bispecific antibodies are reshaping what's possible. Many patients who participate in clinical trials gain access to treatments months or years before they become available through standard pathways—and many achieve meaningful responses that extend survival and improve quality of life.
This comprehensive guide will help you understand the current clinical trial landscape for lung cancer, explore the types of trials available, and provide a clear roadmap for finding and enrolling in trials that match your diagnosis, stage, and treatment history.
The Lung Cancer Clinical Trial Landscape
Scale and Scope
The lung cancer clinical trial ecosystem is remarkably robust. According to ClinicalTrials.gov data, lung cancer represents approximately 18% of all active cancer clinical trials, which reflects both the disease's prevalence and the intense research effort to develop better treatments. These trials span every stage of disease, every major histology, and virtually every therapeutic approach.
Active Trial Categories
The current landscape includes several major trial categories:
Immunotherapy Trials: Immunotherapy has revolutionized lung cancer treatment, and trials continue to explore combinations, optimal sequencing, and applications across disease stages. Checkpoint inhibitors, CAR-T approaches, and novel immune-activating strategies represent a substantial portion of active trials.
Targeted Therapy Trials: For patients with biomarker-positive tumors (EGFR mutations, ALK rearrangements, ROS1 fusions, KRAS G12C mutations, and others), targeted therapy trials test next-generation inhibitors designed to overcome resistance and improve efficacy.
Combination Regimen Trials: Many trials explore synergistic combinations like immunotherapy plus chemotherapy, targeted therapy plus immunotherapy, or entirely novel combinations designed to attack tumors through multiple pathways simultaneously.
Novel Mechanism Trials: Exciting new drug classes are entering trials, including ADCs (antibody-drug conjugates), bispecific antibodies, and therapies targeting emerging biomarkers like MET exon 14 skipping, NTRK fusions, and others.
Prevention and Early Detection Trials: Beyond treating existing cancer, trials are investigating strategies to prevent lung cancer in high-risk populations and detect it earlier through advanced screening methods like low-dose CT and blood-based biomarkers.
Quality of Life and Supportive Care Trials: Recognizing that symptom management and quality of life matter profoundly, trials are testing interventions to minimize side effects, manage fatigue, improve nutrition, and support emotional well-being throughout treatment.
Types of Lung Cancer Clinical Trials
Understanding the different types of clinical trials helps you identify which might align with your needs and goals.
Treatment Trials
Treatment trials test new therapeutic approaches or combinations in patients with diagnosed lung cancer. These include:
Phase I trials: Typically involve 20–100 patients and focus on safety, dosage, and side effects of a new treatment.
Phase II trials: Involve 100–500 patients and assess whether the treatment works for specific cancers and refine optimal dosing.
Phase III trials: Involve 1,000–5,000 patients and compare a new treatment to the current standard of care to determine if it's more effective.
Phase IV trials: Monitor treatments after FDA approval to track long-term effectiveness and side effects.
Many lung cancer patients will explore treatment trials as part of their standard care pathway, particularly after initial treatments or if their cancer becomes resistant to existing therapies.
Prevention Trials
Prevention trials enroll people at high risk for lung cancer—typically those with a significant smoking history, occupational exposures, or genetic predisposition—to test whether certain interventions can reduce cancer risk. These trials might involve medications, dietary supplements, or screening approaches.
Screening and Early Detection Trials
These trials test improved methods for identifying lung cancer earlier, when it's most treatable. Many focus on blood-based biomarkers, advanced imaging techniques, or refined screening criteria that could catch cancer at earlier stages and improve outcomes.
Supportive Care and Quality of Life Trials
These clinical trials address the side effects and symptoms associated with lung cancer and its treatment. They might test interventions to manage fatigue, improve appetite, reduce neuropathy, manage anxiety and depression, or support patients' overall well-being and function during and after treatment.
Clinical Trials for NSCLC
Non-small cell lung cancer accounts for approximately 80–85% of all lung cancers, according to 2026 cancer statistics published in CA: A Cancer Journal for Clinicians, and is the most active area of lung cancer research. The trial landscape for NSCLC is exceptionally diverse and rapidly evolving.
Targeted Therapy Trials for Specific Mutations
EGFR-Mutant NSCLC: For patients whose tumors have EGFR mutations, trials are evaluating third- and fourth-generation EGFR inhibitors designed to overcome acquired resistance. These include agents targeting uncommon EGFR mutations and combinations that address both EGFR and other resistance mechanisms.
ALK-Rearranged NSCLC: ALK-positive patients have access to multiple generations of ALK inhibitors through trials and standard care. Current trials focus on agents with improved CNS penetration, activity against resistant mutations, and combination approaches.
ROS1-Rearranged NSCLC: Though less common, ROS1 fusion-positive NSCLC has several effective targeted therapy options, and trials continue exploring next-generation inhibitors and combinations for patients who develop resistance.
KRAS G12C-Mutant NSCLC: The approval of KRAS G12C inhibitors represents a landmark achievement, and clinical trials are now exploring combinations of KRAS inhibitors with immunotherapy or other targeted agents to maximize efficacy.
Other Emerging Biomarkers: Trials are actively investigating treatments for BRAF mutations, MET exon 14 skipping, NTRK fusions, HER2 mutations, and other rare alterations, ensuring that patients with these mutations have access to targeted approaches.
Immunotherapy Combination Trials
Checkpoint Inhibitor Combinations: Trials are testing various combinations of PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, and other immune checkpoint molecules to enhance anti-tumor responses across different NSCLC populations.
First-Line Immunotherapy + Chemotherapy: Many trials explore immunotherapy combined with chemotherapy as first-line treatment for advanced NSCLC, particularly in patients without actionable biomarkers.
Immunotherapy + Targeted Therapy: These trials test synergistic combinations in biomarker-positive patients, exploring whether dual approaches can improve responses and overcome resistance.
Neoadjuvant and Adjuvant Immunotherapy Trials
Increasingly, immunotherapy is being studied in the neoadjuvant setting (before surgery) and adjuvant setting (after surgery) for earlier-stage NSCLC. These trials have demonstrated that immunotherapy can improve outcomes even in patients with surgically resectable disease.
ADC and Bispecific Antibody Trials
Novel drug classes are transforming NSCLC treatment. ADCs — antibodies linked to potent cell-killing compounds — and bispecific antibodies that engage both tumor and immune cells represent an exciting frontier. Trials are evaluating these agents in various NSCLC subtypes and in combination with other therapies.
Clinical Trials for SCLC
Small cell lung cancer historically had fewer treatment options and a darker prognosis than NSCLC. However, the clinical trial landscape for SCLC is changing, offering new hope.
Immunotherapy + Chemotherapy Combinations
For decades, chemotherapy was the primary treatment for SCLC. A landmark 2018 trial published in the New England Journal of Medicine demonstrated that adding atezolizumab to platinum-etoposide chemotherapy improved survival in extensive-stage SCLC, helping to establish immunotherapy combinations as a new standard of care. Current trials continue exploring optimal immunotherapy approaches, sequencing, and duration.
DLL3-Targeting Therapies
DLL3 is a biomarker expressed on many SCLC tumors. Novel DLL3-targeting approaches, including DLL3-directed monoclonal antibodies and bispecific antibodies, have shown promising activity in early trials and are advancing through later-phase clinical trials.
BiTE Therapies
Bispecific T-cell engagers (BiTEs) that link SCLC tumor cells to the patient's own T cells represent another novel approach being explored in clinical trials. These agents harness the immune system's power in a fundamentally new way.
Targeted Therapy in SCLC
Though SCLC is less commonly associated with actionable biomarkers than NSCLC, clinical trials are identifying and evaluating therapies for specific mutations and alterations in SCLC, expanding treatment possibilities for patients with uncommon molecular features.
Growing Optimism
The SCLC clinical trial landscape reflects genuine momentum. According to recent analyses, the number of SCLC clinical trials has increased substantially, and response rates to novel approaches are encouraging. While SCLC remains a challenging disease, the clinical trial landscape offers genuine opportunities for patients to access transformative treatments.
How to Find and Enroll in a Lung Cancer Clinical Trial
Step 1: Discuss With Your Oncologist
Your oncologist is your most valuable resource. Discuss whether a clinical trial might be appropriate for your situation. Your oncologist understands your specific diagnosis, biomarker status, stage, treatment history, and overall health—all critical factors in identifying suitable trials. Many oncologists have established relationships with trial sites and can provide direct referrals.
Step 2: Search ClinicalTrials.gov
The National Institutes of Health maintains ClinicalTrials.gov, a comprehensive registry of clinical trials worldwide. You can search by condition (lung cancer), location, trial phase, recruitment status, and other criteria. ClinicalTrials.gov provides detailed information about each trial, including contact information for trial sites.
To use ClinicalTrials.gov effectively:
Start with "lung cancer" or your specific type (NSCLC, SCLC)
Filter by recruitment status (select "Recruiting" and "Not yet recruiting")
Filter by location to find trials near you
Review trial descriptions, eligibility criteria, and contact information
Save trials that interest you and discuss them with your oncologist
Step 3: Use Trial Matching Services
Trial matching services help identify trials aligned with your specific diagnosis, biomarker profile, stage, and treatment history. These services can be more efficient than manually searching ClinicalTrials.gov, particularly if you have complex eligibility criteria.
North's trial finder is designed specifically for this purpose. By entering your diagnosis, stage, biomarker status, and geographic preferences, you can quickly identify trials actively recruiting patients who match your profile. Trial matching services often have relationships with trial sites and can facilitate referrals.
Step 4: Understand Eligibility Criteria
Every clinical trial has specific eligibility criteria—requirements that determine who can and cannot participate. These might include:
Specific cancer type, stage, or histology
Presence or absence of particular biomarkers
Prior treatment history
Organ function requirements
Performance status (ability to perform daily activities)
Other health conditions
Eligibility criteria exist for scientific and safety reasons. Take time to carefully review them. If you don't meet criteria for one trial, your oncologist and trial matching services can help identify others where you're eligible.
Step 5: Request Trial Information and Schedule Consultations
Once you've identified promising trials, contact the trial site to request additional information. You can usually reach the trial site through contact information listed on ClinicalTrials.gov or through trial matching services. The trial team can answer questions and determine if you might be a candidate.
Step 6: Understand Informed Consent
Before enrolling in any clinical trial, you'll participate in the informed consent process. This involves detailed discussions with the trial team about:
The trial's purpose and design
What treatments you'll receive
Potential benefits and risks
Your rights and responsibilities
How your data will be used
Informed consent is continuous. You'll have opportunities to ask questions throughout your participation, and you can withdraw from a trial at any time. Never feel pressured to enroll. Take time to understand the trial fully before committing.
Step 7: Enrollment and Baseline Assessments
If you decide to enroll, you'll complete baseline assessments—blood tests, imaging, and other evaluations that establish your health status before treatment begins. These baseline measures allow researchers to track how treatment affects you.
What to Expect During a Lung Cancer Clinical Trial
Trial Schedule and Visits
Clinical trials typically involve regular clinic visits for treatment administration, monitoring, and assessments. The frequency depends on the trial phase and treatment. Early-phase trials might require weekly visits; later-phase trials might space visits out over several months.
Your trial team will provide a detailed schedule outlining visit frequency, what happens at each visit, and what preparation (like fasting or medication adjustments) might be necessary. Understanding this schedule helps you plan your life around trial participation.
Monitoring and Safety Assessment
Throughout the trial, you'll undergo regular assessments to monitor your response to treatment and identify any adverse events (side effects). These assessments might include:
Blood tests to evaluate organ function and blood cell counts
Imaging studies (CT scans, PET scans) to assess tumor response
Electrocardiograms (ECGs) to monitor heart function if relevant
Physical exams and symptom assessments
Your trial team will carefully track all adverse events and communicate with you about what you're experiencing. If serious side effects emerge, your treatment might be adjusted or discontinued.
Communication With Your Trial Team
Maintain open communication with your trial team. Report all symptoms, side effects, and concerns promptly. If you're experiencing significant side effects, don't wait for your next scheduled visit—contact your trial team immediately. Most trials have on-call support for urgent issues.
Costs and Insurance Coverage
Clinical trial participation typically doesn't cost you money for the investigational treatment itself—the trial sponsor covers those costs. However, you should understand:
Covered costs: The investigational treatment, research-related tests and assessments, and clinic visits specific to the trial
Potentially uncovered costs: Routine medical care, travel to the trial site, and time off work
Insurance role: Your insurance might still cover routine cancer care not part of the trial, but always clarify this before enrollment
Ask your trial team specifically about costs and insurance coverage before enrolling. They can often facilitate discussions with your insurance company to clarify what will be covered.
Support Services
Many trials offer support services including:
Nutritional counseling and dietitian support
Mental health and counseling services
Assistance with travel and accommodations
Coordination with your outside oncologist
Financial assistance programs
Don't hesitate to ask your trial team what support services are available.
Questions to Ask About a Lung Cancer Clinical Trial
Before enrolling in a clinical trial, ask these essential questions:
About the Trial's Purpose and Design
What is the primary purpose of this trial? What question is it trying to answer?
What phase is this trial? (Phase I, II, III, or IV?)
How is the trial designed? Will I be randomized (randomly assigned) to different treatment groups?
About Treatment and Expectations
What is the investigational treatment? How does it work?
If I'm randomized, what are the possible treatment groups?
Will there be a placebo (inactive treatment)? If so, what's the chance I'll receive it?
What is the expected duration of treatment?
What response rates or benefit(s) have been observed in previous trials or early data?
About Risks and Benefits
What are the known side effects or adverse events associated with this treatment?
How is the trial designed to monitor and manage side effects?
What happens if I experience serious side effects?
Do you have examples of how previous trial participants have responded?
About Logistics and Commitment
Where will trial visits take place?
How often will I need to visit the clinic?
How much time should I plan for each visit?
Will I need tests or procedures between visits?
Can I continue seeing my regular oncologist?
About Costs and Insurance
What costs will the trial cover?
Will my insurance be billed? For what services?
Are there co-pays or other out-of-pocket costs?
Is financial assistance available for travel or other expenses?
About Your Rights and Flexibility
Can I withdraw from the trial at any time?
If I withdraw, what happens to my care?
How will you protect my privacy and data?
Who do I contact if I have questions or concerns?
What is your process for reporting and addressing adverse events?
Frequently Asked Questions
What does "randomization" mean in a clinical trial?
Randomization means you're randomly assigned to different treatment groups in the trial—sometimes the new investigational treatment, sometimes the standard treatment, and occasionally a placebo. Randomization is controlled by a computer algorithm to ensure fairness and eliminate bias. Researchers use randomization to create groups that are as similar as possible at the start, so differences in outcomes can be attributed to the treatment rather than pre-existing differences between groups. Your trial team will explain the randomization process and your chances of being assigned to each group before you enroll.
Will I have to pay for treatment in a clinical trial?
No—clinical trials are sponsored by pharmaceutical companies, academic institutions, or government agencies that cover the cost of the investigational treatment and most research-related tests and visits. However, you may have costs for routine medical care that's not part of the trial, and you might have travel costs or time away from work. Before enrolling, ask your trial team specifically about what's covered, whether your insurance will be billed for routine care, and whether any assistance is available for travel or other expenses.
Can I stop participating in a clinical trial at any time?
Yes, absolutely. Participation in clinical trials is entirely voluntary, and you can withdraw at any time without affecting your medical care or your relationship with your healthcare providers. If you decide to withdraw, your trial team will discuss what ongoing care you need and coordinate with your oncologist. Some trials do ask that you complete certain final assessments to ensure your safety after withdrawing.
What if the clinical trial treatment stops working or causes unacceptable side effects?
Your trial team continuously monitors your response and adverse events. If treatment isn't working or side effects are unacceptable, your trial team can adjust your dose, switch you to a different treatment, or discuss discontinuing the trial. Your health and safety are the top priority. Additionally, if early trial data shows that one treatment approach is clearly better than another, the trial might be modified so all participants receive the more effective approach.
How can I find clinical trials if my oncologist doesn't mention them?
Start by visiting ClinicalTrials.gov and searching for lung cancer trials in your area. You can also contact major cancer centers or academic medical centers near you—they typically have trial coordinators who can help identify appropriate options. Trial matching services like North's trial finder can also help identify relevant trials. Don't hesitate to take an active role in this search—your oncologist can review any trials you find and provide guidance on whether they're appropriate for you.
Clinical trials represent a genuine opportunity to access cutting-edge treatments while contributing to research that advances care for all lung cancer patients. Whether you're exploring options for newly diagnosed disease, managing advanced cancer, or seeking new approaches after prior treatments, trials can offer hope and possibility.
Use North's trial finder to search for trials matching your diagnosis, stage, and treatment history. Our tool is designed to make trial discovery straightforward and accessible. Simply enter your information, and we'll identify active trials recruiting patients like you. Your journey toward innovative treatment options starts here.
Related resources:
References
National Cancer Institute. "Clinical Trials Information for Patients and Caregivers." cancer.gov.
U.S. National Library of Medicine. "ClinicalTrials.gov." clinicaltrials.gov.
American Cancer Society. "Clinical Trials." cancer.org.
National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 3.2026." nccn.org.
Herbst RS, Morgensztern D, Boshoff C. "The Biology and Management of Non-Small Cell Lung Cancer." Nature. 2018;553(7689):446–454.
Oronsky B, Abrouk N, Caroen S, et al. "A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)." Journal of Cancer. 2022;13(9):2945–2953.
Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. "Cancer Statistics, 2026." CA: A Cancer Journal for Clinicians. 2026. doi: 10.3322/caac.70043.
Horn L, Mansfield AS, Szczęsna A, et al. "First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer." New England Journal of Medicine. 2018;379(23):2220–2229.
